Selected Portfolio Companies

Golden Pine Ventures has founded and launched several biotechnology and biomedical companies, including:

Pique Therapeutics, Inc.
Pique Therapeutics is a biotechnology company seeking to become the leader in therapeutic vaccines, focused initially on the treatment of cancer.  Pique’s lead product is a first-in-class therapeutic vaccine for non-small cell lung cancer in Phase 2 clinical trials. Pique is also utilizing its novel therapeutic vaccine technology in additional areas of oncology, with products in pre-clinical stage for pancreatic, colorectal, and head and neck cancers.

Alterna Therapeutics, Inc.
Alterna Therapeutics is a biotechnology company developing a library of first-in-class small molecules targeting the SHIP enzyme.  In obesity, SHIP inhibition promotes the survival of immunoregulatory cell types in fat tissue that are known to limit inflammation, and thus can reverse obesity and normalize blood sugar control. Alterna’s lead compounds have shown efficacy in multiple animal models of obesity and diabetes. Alterna Therapeutics is based on technology licensed from SUNY Upstate Medical University and Syracuse University, developed primarily by Dr. William G. Kerr, Professor of Microbiology and Immunology and Pediatrics at SUNY Upstate Medical.

Kylin Therapeutics, Inc.
Kylin Therapeutics, a cutting-edge biotechnology company, employs a revolutionary RNA nanoparticle technology platform called “pRNA” to exploit the enormous potential of RNA interference (RNAi) for treatment of many common diseases.  The visionary platform has enormous potential to meet the huge market opportunity for treating cancer and other diseases with RNA-based therapeutics.  The unique capabilities of the platform have enabled Kylin to overcome the most significant challenges in the development of RNA-based therapies.

Kylin Therapeutics was acquired in 2012.